Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : XOMA. Bull or Bear? -- Ignore unavailable to you. Want to Upgrade?

To: Bluegreen who wrote (12402)	12/7/1999 10:38:00 AM
From: aknahow	Read Replies (2) \| Respond to of 17367

You are correct if you mean that as a joke. One really should mark to market and a loss is a loss regardless of ones selling the stock or not. BTW I have heard that the information being released on Psoriasis hu1124 shows it performing well. A biased source even said better than the Biogen drug. This is not clear to me as I have not seen the information nor am I sure I would be able to compare it correctly to other data. Anyone who gets the data please post whatever seems to be significant. Also it is regrettable that neither DNA nor XOMA have had any release on their presentations. It is a bit difficult to believe that DNA/XOMA really have something better when they themselves have made no p.r. release.